76858-72-5

Upstream product

• 13726-52-8 diethyl N-(p-aminobenzoyl)-L-glutamate 
• 106-96-7 propargyl bromide 

Downstream Products

• 101773-16-4 diethyl benzoyl>-L-glutamate 
• 130379-75-8 (S)-2-{4-[(2-Acetoxymethyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-prop-2-ynyl-amino]-benzoylamino}-pentanedioic acid diethyl ester 
• 1054791-41-1 2-(4-{[2-(2,2-dimethyl-propionylamino)-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl]-prop-2-ynyl-amino}-benzoylamino)-pentanedioic acid diethyl ester 
• 106585-54-0 diethyl N-<4--6-quinazolinyl>methyl>prop-2-ynylamino>benzoyl>-L-glutamate 
• 76858-74-7 diethyl N¹⁰-propargyl-5,8-dideazafolic acid 
• 123637-30-9 N-[4-[N-(3,4-dichloroquinolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoyl]-L-glutamic acid 
• 123637-29-6 N-[4-[N-(2-chloro-3-hydroxymethylquinolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoyl]-L-glutamic acid 
• 123636-81-7 N-[4-[N-(3-amino-4-chloroquinolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoyl]-L-glutamic acid 
• 123636-76-0 N-[4-[N-(2-amino-4-chloroquinolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoyl]-L-glutamic acid 
• 112887-62-4 N-p-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoyl-L-glutamic acid 
• 112887-73-7 N-p-[N-(3,4dihydro-2-hydroxymethyl-4-oxoquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoyl-L-glutamic acid 
• 112887-86-2 (S)-2-{4-[(2-Isopropyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-prop-2-ynyl-amino]-benzoylamino}-pentanedioic acid 
• 131066-84-7 diethyl N-<4-methyl>prop-2-ynylamino>benzoyl>-L-glutamate 
• 131066-87-0 N-<4-prop-2-ynylamino>benzoyl>-L-glutamic acid 

Relevant academic research and scientific papers

Folic acid-conjugated europium complexes as luminescent probes for selective targeting of cancer cells

We report the synthesis of three optical probes (Eu3+1, Eu3+2, and Eu3+3) having a luminescent Eu complex (signaling unit) bonded in different positions to folic acid (FA), the folate receptor (FR) targeting unit. The structures of the two regioisomers Eu3+1 and Eu3+2 were assigned by mass spectrometric experiments. The optical properties and stability of these probes were assessed in phosphate-buffered saline, cell culture medium, rat serum, and cellular lysate, and results indicated that they are chemically and photophysically stable. Cytotoxicity was studied with ovarian cancer cells having high (SKOV-3), intermediate (OVCAR-3), low (IGROV-1), or null (A2780) expression of FRs. The internalized probe, evaluated in SKOV-3, IGROV-1, and A2780 cells, was in the order Eu3+2 > Eu3+1 > Eu3+3. No internalization was observed for A2780 cells. Such results, together with those obtained in competition experiments of FA versus Eu3+2 and FA or Eu3+2 versus 3H-FA, indicate that internalization is receptor-mediated and that Eu3+2 shows high selectivity and specificity for FR.

2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes

Based on our previous results on the ascertained potent growth inhibition effect against a panel of 60 human tumors cell lines at National Cancer Institute of Bethesda (NCI), we have synthesized a novel series of thirty-one 2-[N-methyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines (1-31). The lead compound 1 was previously reported to be endowed with significant inhibition against hDHFR enzyme, with a Ki of 0.2 μM. Docking studies were performed on compound 1 and here reported to predict its binding conformation to human dihydrofolate reductase (hDHFR). All compounds (1-31) were assayed versus hDHFR and human thymidylate synthase (hTS). From the screening emerged that all compounds inhibited hDHFR with Ki values included between 0.2 and 11 μM, while only a few (6, 21, 24, 27, 29) showed great activity and selectivity towards hTS. Evaluation of the anticancer activity was performed by NCI, first against the three cell line panel, and only the most active compounds (17, 21, 24, 26, 27) were evaluated on a panel of 60 human tumor cell lines. Compound 21 was the most active against all cell lines with log GI50 equal to -5.49 and log LC50 equal to -4.19 and maintained significant percent of growth inhibition on seven cancer cell lines at the concentration of 1 μM. Compound 17 was the second most active and moreover showed interesting selectivity against some cell lines (Lung cancer: A549/ATCC, Melanoma: UACC-257, Ovarian Cancer: ovcar-8 and Renal cancer: RXF 393) at all concentration examined (100-0.01 μM).

Quinoline derivatives having anti-tumor activity

The invention relates to a quinoline of the formula: STR1 wherein each of R1 and R2, which may be the same or different, is hydrogen, halogeno, hydroxy, cyano, carbamoyl, nitro or amino, alkyl, alkoxy, alkylthio, alkylamino, dialkyla

Anti-tumor agents

A quinazoline of the formula: STR1 wherein R1 is alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, arylalkyl, halogeno, hydroxy or mercapto, or substituted alkyl or alkoxy; wherein R2 is hydrogen, alkyl

Folate Analogues as Inhibitors of Thymidylate Synthase

Recent demonstrations that deazafolate analogues may act as potent inhibitors of thymidylate synthase (TS) provided a firm rationale for the synthesis of N10-propargyl derivatives of 8-deazafolate (3) and 8-deazaaminopterin (4).A complete assig

Anti-cancer quinazoline derivatives

Quinazoline derivatives of formula: STR1 wherein R represents: (1) a straight or branched chain unsaturated hydrocarbon group, or (2) a straight or branched chain saturated or unsaturated hydrocarbon group which is substituted by at least one: heteroatom,

10-Propargylaminopterin and Alkyl Homologues of Methotrexate as Inhibitors of Folate Metabolism

Reported antifolate activity against leukemia L1210 by N-propargylamino>benzoyl>-L-glutamic acid through potent inhibition of thymidylate synthase (EC 2.1.1.45) prompted us to include the propargyl group in a